News
Novo Nordisk is partnering with the biotech Septerna to develop oral obesity drugs, as it aims for more convenient weight ...
Meanwhile, Eli Lilly's Zepbound injection has gained traction, prompting both firms to race toward more convenient ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback